The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Update of the guidelines for lupus anticoagulant detection
Open accessAbstract
One of the conclusions of the subcommittee meeting on Lupus Anticoagulant/Phospholipid dependent antibodies, held in Geneva on 2007, was the need to update the guidelines on Lupus Anticoagulant (LA) detection. Particular emphasis was given to several aspects discussed in this official communication. A new paragraph is dedicated to the patient selection, and aims to minimize inappropriate requests for LA testing. Modalities for blood collection and processing are fully delineated and the choice of tests is limited to dRVVT and a sensitive aPTT. Calculation of cut-off values for each diagnostic step are clearly stated. A final paragraph reports the interpretation of the results in general and in particular situations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, persistently positive LAC and/or moderate/high Sapporo criteria aPL Abs (aCL IgG or IGM, or anti-b2GPI IgG or IgM) (10) were associated with HCQ use, OR 0.24 (0.06, 0.94), p=0.04”
From Hydroxychloroquine Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in Systemic Lupus Erythematosus (2013) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last update of the guidelines for LA detection by the International Society on Thrombosis and Haemostasis Scientific and Standardization Subcommittee (ISTH-SSC) in 2009 12 has proven useful in achieving greater uniformity in performance and interpretation of LA testing.”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, on other points, including testing in patients on anticoagulation, cutoff values, and calculation and interpretation of results, there was uncertainty or lack of agreement.12,15”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For samples from patients with no other causes of clotting time prolongation and LA assay confirmatory test results within reference intervals, the increasingly popular paradigm of integrated testing is sufficient to detect the presence of LA without performing the mixing test at all.6, 7, 8, 9, 26, 27, 28, 31, 33, 34”
From Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant (2018) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mixing test is mainly to discriminate between the presence of an inhibitor and coagulation factor deficiencies such as those occurring in patients on conventional oral anticoagulants/vitamin K antagonists (VKA).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Guidelines recommend mixing tests are interpreted with either a mixing test specific cut‐off (MTC) or the index of circulating anticoagulant (ICA).”
The cited source says what the claim attributes to it.
In the citing paper
“There is no single test to detect all LA1, 6, 7, 8 and guidelines recommend performance of two different tests that represent different assay principles, the diluted Russell's viper venom time (dRVVT) and a LA‐sensitive activated partial thromboplastin time (APTT).6, 7, 8”
The cited source says what the claim attributes to it.
In the citing paper
“LA positivity was determined following the Scientific and Standardization Committee (SSC)/International Society on Thrombosis and Hemostasis (ISTH) recommendations at the time of testing.11,13”
From Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“The lupus anticoagulant assay (LA) followed international guidelines for the performance of this functional assay (54).”
From Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA (2019) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“According to ISTH/SSC (1) and CLSI (2) guidelines LAC identification should include three steps: screening for prolongation in a phospholipid-sensitive test, mixing with normal plasma to identify failure to correct and confirmation through result shortening in a phospholipid-rich test, (though in slightly different priority with CLSI).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Results were expressed as normalized ratios and interpreted according to in-house calculated cut-off values calculated with the 99th percentile (1).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Testing patients during VKA or other anticoagulant therapy for LAC remains a contentious issue and has been discouraged by official guidelines (1, 2) because of interpretational problems affecting the mixing test (8-10).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Because there is no single assay sensitive to all LA antibodies, at least 2 coagulation tests based on different assay principles are recommended for LA detection [[11], [12], [13]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Various interpretation indices, including percentage of correction (%Correct), screen-to-confirm ratio (SCR), and normalized SCR (NSCR), are suggested to determine the presence of LA in these phospholipid-dependent assays [[11], [12], [13]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Laboratory tests for LA detection comprise complex and multistep coagulation testing procedures, including screening, confirmatory, and mixing tests [[11], [12], [13]], and heterogeneity in these is an important cause of interlaboratory variation.”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“The diluted Russell’s viper venom time (dRVVT) assay is the first recommended test for detecting LA due to its high sensitivity and specificity [14], while the LA-sensitive activated partial thromboplastin time (aPTT) assay can be used as a secondary test [[11], [12], [13], [14]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“LAC was determined using the STA-R Evolution Coagulation Analyzer (Diagnostica Stago, Asnières-sur-Seine, France) according to ISTH guidelines 1 applying dilute Russell ' s viper venomtime (dRVVT Screen and dRVVT Confirm, Diagnostica Stago, Asnières-sur-Seine, France) and a sensitive activated partial thromboplastin time (aPTT) with silica as an activator (PTT-LA, Diagnostica Stago, Asnières-sur-”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“This study supports the dRVVT as the preferred assay to detect LAC. 1”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“and LAC was performed according to the ISTH guidelines. 1,34”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“LA was determined using two clotting assays as recommended by the 2009 International Society on Thrombosis and Haemostasis (ISTH) guidelines, 21 which were applicable at the time of the study: APTT by Diagnostica Stago and dRVVT by HYPHEN BioMed. 21”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“However, the samples were analyzed before the publication of these new guidelines and therefore interpreted according to the guidelines that were applicable at this time. 21”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [21]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The majority of survey participants indicated that the number should be at least 40, which seems reasonable to guarantee an overall normal clotting factor activity. 12”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citationBrandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
Rand, J. H., Wu, X.-X., Quinn, A. S., Chen, P. P., Hathcock, J. J., & Taatjes, D. J. (2008) · Blood · doi:10.1182/blood-2008-03-144204 · Cited by 215
Self-citationDetection and Quantitative Evaluation of Lupus Circulating Anticoagulant Activity
Rosner, E., Pauzner, R., Lusky, A., Modan, M., & Many, A. (1987) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651083 · Cited by 188
Galli, M., Finazzi, G., Bevers, E. M., & Barbui, T. (1995) · Blood · doi:10.1182/blood.v86.2.617.bloodjournal862617 · Cited by 146
Self-citationA Hexagonal (II) Phase Phospholipid Neutralization Assay for Lupus Anticoagulant Identification
Triplett, D. A., Barna, L. K., & Unger, G. A. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649671 · Cited by 132
The Textarin/Ecarin Ratio: A Confirmatory Test for Lupus Anticoagulants
Triplett, D. A., Stocker, K. F., Unger, G. A., & Barna, L. K. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649701 · Cited by 110
Jennings, I., Kitchen, S., Woods, T. A. L., Preston, F. E., & Greaves, M. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656080 · Cited by 103
Meijer, P., Vermylen, J., & Arnout, J. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614601 · Cited by 96
Cited by
Sorted by citations
Items 201–300 of 1,001
Ortel, T. L., Meleth, S., Catellier, D., Crowther, M. A., Erkan, D., Fortin, P. R., Garcia, D. A., Haywood, N., Kosinski, A. S., Levine, S. R., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14936 · Cited by 46
Self-citationFrans, G., Meeus, P., & Bailleul, E. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14488 · Cited by 44
Zuily, S., Regnault, V., Guillemin, F., Kaminsky, P., Rat, A., Lecompte, T., & Wahl, D. G. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.04.012 · Cited by 44
Bertero, M., Bazzan, M., CARIGNOLA, R., Montaruli, B., Silvestro, E., Sciascia, S., Vaccarino, A., Baldovino, S., & Roccatello, D. (2012) · Lupus · doi:10.1177/0961203312446974 · Cited by 44
Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?
Cohen, H., & Machin, S. J. (2010) · Lupus · doi:10.1177/0961203310361355 · Cited by 43
Critical pre-examination variables in the hemostasis laboratory and their quality indicators
Adcock, D. M., Favaloro, E. J., & Lippi, G. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.08.022 · Cited by 43
Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome
Iwaniec, T., Kaczor, M. P., Celińska‐Löwenhoff, M., Polański, S., & Musiał, J. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.02.019 · Cited by 43
Mosteirín, N. F., Comet, L. S., Osuna, C. S., Villas, J. M. C., & Marcó, J. (2017) · Lupus · doi:10.1177/0961203317703493 · Cited by 43
Alijotas‐Reig, J., Esteve‐Valverde, E., Llurba, E., & Gris, J. M. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.02.006 · Cited by 43
Efthymiou, M., Lawrie, A. S., Mackie, I. J., Arachchillage, D. J., Lane, P. J., Machin, S. J., & Cohen, H. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.03.030 · Cited by 43
Migraineurs show a high prevalence of antiphospholipid antibodies
Cavestro, C., Micca, G., Molinari, F., Bazzan, M., Pietrantonj, C. D., Aloi, R., PEDEMONTE, E., Iannini, R., Frigeri, M. C., & Roccatello, D. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04348.x · Cited by 43
Toulon, P. A., Eloit, Y., Smahi, M., Sigaud, C., Jambou, D., Fischer, F., & Appert‐Flory, A. (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12499 · Cited by 43
DEVREESE, K. M. J. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03807.x · Cited by 42
Moore, G. W., Culhane, A. P., Daw, C. R., Noronha, C. P., & Kumano, O. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.01.019 · Cited by 42
Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study
Martinelli, I., Maino, A., Abbattista, M., Bucciarelli, P., Passamonti, S. M., Artoni, A., Gianniello, F., & Peyvandi, F. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.03.025 · Cited by 42
Meneghel, L., Ruffatti, A., Gavasso, S., Tonello, M., Mattia, E., Spiezia, L., Tormene, D., Hoxha, A., Fedrigo, M., & Simioni, P. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.04.033 · Cited by 42
Antiphospholipid Syndrome Clinical Research Task Force Report
Erkan, D., Derksen, R. H. W. M., Levy, R. A., Machin, S. J., Ortel, T. L., Pierangeli, S. S., Roubey, R. A. S., & Lockshin, M. D. (2011) · Lupus · doi:10.1177/0961203310395053 · Cited by 42
Self-citationInterference of C-reactive protein with clotting times
Devreese, K. M. J., Verfaillie, C. J., De Bisschop, F., & Delanghe, J. R. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0906 · Cited by 42
An Overview of Thrombophilia and Associated Laboratory Testing
Montagnana, M., Lippi, G., & Danese, E. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7196-1_9 · Cited by 42
Jourdi, G., Delrue, M., Stépanian, A., Valaize, J., Foulon‐Pinto, G., Demagny, J., Duchemin, J., Nédelec-Gac, F., Darnige, L., Curis, E., et al. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.11.001 · Cited by 42
Zuily, S., Clerc‐Urmès, I., Bauman, C., ANDRADE, D. C. O. D., Sciascia, S., Pengo, V., Tektonidou, M. G., Ugarte, A., Gerosa, M., Belmont, M. H., et al. (2020) · Lupus · doi:10.1177/0961203320940776 · Cited by 44
Self-citationIs Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature
Favaloro, E. J., Henry, B. M., & Lippi, G. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1729856 · Cited by 43
Conti, F., Perricone, C., Reboldi, G., Gawlicki, M., Bartosiewicz, I., Pacucci, V. A., Massaro, L., Miranda, F., Truglia, S., Alessandri, C., et al. (2014) · Lupus · doi:10.1177/0961203314524466 · Cited by 42
Commonalities and contrasts in recent guidelines for lupus anticoagulant detection
Moore, G. W. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12227 · Cited by 41
Celińska‐Löwenhoff, M., Iwaniec, T., Padjas, A., Musiał, J., & Undas, A. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-11-0980 · Cited by 41
Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE
Petri, M., Conklin, J., O’Malley, T., & Dervieux, T. (2019) · Lupus Science & Medicine · doi:10.1136/lupus-2019-000318 · Cited by 41
Siriez, R., Dogné, J., Gosselin, R. C., Laloy, J., Mullier, F., & Douxfils, J. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13342 · Cited by 41
Gerde, M., Ibarra, E. E. M., Kenzie, R. M., Suarez, C. F., Heer, C., Álvarez, R., Iglesias, M., Balparda, J., Beruti, E., & Rubinstein, F. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.08.004 · Cited by 41
Favaloro, E. J., & Lippi, G. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.061 · Cited by 40
Forastiero, R. R., Papalardo, E., Watkins, M., Nguyen, H. C. T., Quirbach, C., Jaskal, K., Kast, M., Teodorescu, M., Lakos, G., Binder, W. L., et al. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.11.009 · Cited by 40
Arachchillage, D. J., Mackie, I. J., Efthymiou, M., Chitolie, A., Hunt, B. J., Isenberg, D. A., Khamashta, M. A., Machin, S. J., & Cohen, H. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13475 · Cited by 40
Bombini, M. F., Peres, F. A., Lapa, A. T., Sinicato, N. A., Quental, B. R., Pincelli, Á. D. S. M., Amaral, T. N., Gomes, C. C., del Rio, A. P., Marques-Neto, J. F., et al. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.02.002 · Cited by 40
Ruffatti, A., Tarzia, V., Fedrigo, M., Calligaro, A., Favarò, M., Macor, P., Tison, T., Cucchini, U., Cosmi, E., Tedesco, F., et al. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.03.015 · Cited by 40
Cox‐Morton, S., MacDonald, S. G., & Thomas, W. (2019) · British Journal of Haematology · doi:10.1111/bjh.16091 · Cited by 40
De Kesel, P. M., & Devreese, K. M. J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14894 · Cited by 40
Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?
Foret, T., Dufrost, V., du Mont, L. S., Costa, P., Lefèvre, B., Lacolley, P. J., Regnault, V., Zuily, S., & Wahl, D. G. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01029-3 · Cited by 40
Zhu, R., Cheng, C., Yang, Y., Denas, G., & Pengo, V. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.04.021 · Cited by 40
Self-citationShehata, H. A., Ali, A., Silva-Edge, M., Haroon, S., Elfituri, A., Viswanatha, R., Jan, H., & Akolekar, R. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059519 · Cited by 40
Saraiva, S. D. S., Custódio, I., Mazetto, B. D. M., Colella, M. P., Paula, E. V. D., Appenzeller, S., Annichino-Bizzachi, J., & Orsi, F. A. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.10.029 · Cited by 40
Kotzen, E., Roy, S., & Jain, K. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.012 · Cited by 40
The antiphospholipid syndrome – often overlooked cause of vascular occlusions?
Svenungsson, E., & Antovič, A. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13022 · Cited by 39
Gendron, N., Dragon‐Durey, M., Chocron, R., Darnige, L., Jourdi, G., Philippe, A., Chenevier‐Gobeaux, C., Hadjadj, J., Duchemin, J., Khider, L., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41777 · Cited by 39
Primary Adrenal Insufficiency Due to Bilateral Adrenal Infarction in COVID-19
Machado, I. F. R., Menezes, I. Q., de Figueiredo, S. R., Coelho, F. M. A., Terrabuio, D. R. B., Ramos, D. V., Fagundes, G. F. C., Maciel, A. A. W., Latronico, A. C., Fragoso, M. C. B. V., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab557 · Cited by 39
Induction of anti‐β2‐glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes
OS, G. M. A. V., Meijers, J. C. M., Ağar, Ç., Serón, M. V., Marquart, J. A., Åkesson, P., Urbanus, R. T., Derksen, R. H. W. M., Herwald, H., Mörgelin, M., et al. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04532.x · Cited by 39
Rogers, H. J., Nakashima, M. O., & Kottke‐Marchant, K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-47913-4.00002-1 · Cited by 39
Treatment of the antiphospholipid syndrome
Galli, M. (2013) · Autoimmunity Highlights · doi:10.1007/s13317-013-0056-5 · Cited by 38
Self-citationBao, S., Sheng, S. L., Liao, H., Zhou, Q., Frempong, S. T., & Tu, W. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12770 · Cited by 38
Minno, M. N. D. D., Emmi, G., Ambrosino, P., Scalera, A., Tufano, A., Cafaro, G., Peluso, R., Bettiol, A., Scala, G. D., Silvestri, E., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.06.010 · Cited by 38
Kremers, R., Zuily, S., Kelchtermans, H., Peters, T. C., Bloemen, S., Regnault, V., Hemker, H. C., de Groot, P. G., Wahl, D. G., & de Laat, B. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018018036 · Cited by 38
Tonello, M., Mattia, E., Favarò, M., Ross, T. D., Calligaro, A., Salvan, E., Hoxha, A., Fedrigo, M., & Ruffatti, A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.03.006 · Cited by 38
Jiang, X., Du, Y., Cheng, C., Denas, G., Zhou, Y., Wu, T., Zhang, Y., Han, Z.-Y., Pengo, V., & Jing, Z. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1692428 · Cited by 40
Self-citationTesting for antiphospholipid antibodies: Advances and best practices
Devreese, K. M. J. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13195 · Cited by 39
Zuily, S., de Laat, B., Guillemin, F., Kelchtermans, H., Magy-Bertrand, N., Desmurs‐Clavel, H., Lambert, M., Poindron, V., de Maistre, E., Dufrost, V., et al. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa072 · Cited by 38
Anticoagulant Effect of Sugammadex
Dirkmann, D., Britten, M. W., Pauling, H., Weidle, J., Volbracht, L., Görlinger, K., & Peters, J. (2016) · Anesthesiology · doi:10.1097/aln.0000000000001076 · Cited by 38
Meneghel, L., Ruffatti, A., Gavasso, S., Tonello, M., Mattia, E., Spiezia, L., Campello, E., Hoxha, A., Fedrigo, M., Punzi, L., et al. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0925 · Cited by 37
APS - Diagnostics and challenges for the future
Pengo, V., Bison, E., Zoppellaro, G., Jose, S. P., Denas, G., Hoxha, A., Ruffatti, A., & Banzato, A. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.028 · Cited by 37
Self-citationWatanabe, T., Oku, K., Amengual, O., Hisada, R., Ohmura, K., Nakagawa, I., Shida, H., Bohgaki, T., Horita, T., Yasuda, S., et al. (2017) · Lupus · doi:10.1177/0961203317716787 · Cited by 38
Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective
Pengo, V., & Denas, G. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.011 · Cited by 37
Self-citationHisada, R., Kato, M., Ohnishi, N., Sugawara, E., Fujieda, Y., Oku, K., Bohgaki, T., Amengual, O., Yasuda, S., & Atsumi, T. (2018) · Rheumatology · doi:10.1093/rheumatology/key365 · Cited by 37
How to report results of prothrombin and activated partial thromboplastin times
Tripodi, A., Lippi, G., & Plebani, M. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0657 · Cited by 37
Self-citationAntiphospholipid Antibody Syndrome
Kutteh, W. H., & Hinote, C. D. (2014) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2013.10.004 · Cited by 37
Yin, D., de Groot, P. G., Ninivaggi, M., Devreese, K. M. J., & de Laat, B. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1344-4271 · Cited by 36
Favaloro, E. J., & Wong, R. C. W. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.064 · Cited by 36
The challenges of lupus anticoagulants
Chighizola, C. B., Raschi, E., Banzato, A., Borghi, M. O., Pengo, V., & Meroni, P. L. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1140034 · Cited by 36
Self-citationCurrent Controversies in Lupus Anticoagulant Detection
Moore, G. (2016) · Antibodies · doi:10.3390/antib5040022 · Cited by 36
Chinnaraj, M., Planer, W., Pengo, V., & Pozzi, N. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019030932 · Cited by 36
Self-citationBarbosa, A. C. N., Montalvão, S. A. D. L., Barbosa, K. G. N., Colella, M. P., Annichino‐Bizzacchi, J. M., Ozelo, M. C., & Paula, E. V. D. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12252 · Cited by 36
Antiphospholipid syndrome: a clinical perspective
Zuo, Y., Shi, H., Li, C., & Knight, J. S. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000705 · Cited by 39
Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines
Swadźba, J., Iwaniec, T., PULKA, M., de Laat, B., de Groot, P. G., & Musiał, J. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04420.x · Cited by 36
Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay
Egerer, K., Roggenbuck, D., Büttner, T., Lehmann, B., Kohn, A., von Landenberg, P., Hiemann, R., Feist, E., Burmester, G. R., & Dörner, T. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3421 · Cited by 36
Laboratory Diagnostics of Antiphospholipid Syndrome
Bison, E., Denas, G., Jose, S., Zoppellaro, G., Banzato, A., & Pengo, V. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1601331 · Cited by 37
Self-citationTripodi, A., Chantarangkul, V., Cini, M., Devreese, K., Dlott, J. S., Giacomello, R., Gray, E., Legnani, C., Martinuzzo, M. E., Pradella, P., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13678 · Cited by 35
Self-citationIsert, M., Miesbach, W., Schüttfort, G., Weil, Y., Tirneci, V., Kasper, A., Weber, A., Lindhoff‐Last, E., Herrmann, E. M., & Linnemann, B. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2374-3 · Cited by 35
Devreese, K. M. J., Poncet, A., Lindhoff‐Last, E., Musiał, J., de Moerloose, P., & Fontana, P. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13560 · Cited by 35
Ruffatti, A., Silvestro, G. D., Marson, P., Tonello, M., Calligaro, A., Favarò, M., Ross, T. D., Hoxha, A., Mattia, E., & Pengo, V. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.07.001 · Cited by 35
Self-citationAutoantibodies in connective tissue disease
Mulhearn, B., Tansley, S., & McHugh, N. J. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.101462 · Cited by 35
How to Interpret Antiphospholipid Laboratory Tests
Devreese, K. M. J. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00916-5 · Cited by 36
Lupus anticoagulant and mortality in patients hospitalized for COVID-19
Gazzaruso, C., Mariani, G., Ravetto, C., Malinverni, L., Tondelli, E., Cerrone, M., Sala, V., Bevilacqua, L., Altavilla, T., Coppola, A., et al. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02335-w · Cited by 35
Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent
Vollmer, O., Tacquard, C. A., Dieudonné, Y., Nespola, B., Sattler, L., Grunebaum, L., Gies, V., Radosavljevic, M., Kaeuffer, C., Hansmann, Y., et al. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102822 · Cited by 35
Antiphospholipid syndrome: critical analysis of the diagnostic path
Pengo, V., Banzato, A., Bison, E., Denas, G., Jose, S. P., & Ruffatti, A. (2010) · Lupus · doi:10.1177/0961203309360543 · Cited by 35
Self-citationArachchillage, D. J., Efthymiou, M., Mackie, I. J., Lawrie, A. S., Machin, S. J., & Cohen, H. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.037 · Cited by 35
Determining the effect of freezing on coagulation testing
Gosselin, R. C., & Dwyre, D. M. (2014) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000184 · Cited by 35
The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study
Radin, M., Schreiber, K. I., Cecchi, I., Roccatello, D., Cuadrado, M. J., & Sciascia, S. (2017) · European Journal of Neurology · doi:10.1111/ene.13499 · Cited by 35
Dilute Russell's viper venom time reagents in lupus anticoagulant testing: a well‐considered choice
Depreter, B., & Devreese, K. M. J. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0245 · Cited by 34
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome
Hoxha, A., Ruffatti, A., Tonello, M., Bontadi, A., Salvan, E., Banzato, A., Pengo, V., & Punzi, L. (2012) · Lupus · doi:10.1177/0961203312441983 · Cited by 34
Self-citationNon-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome
Sciascia, S., López-Pedrera, C., Cecchi, I., Pecoraro, C., Roccatello, D., & Cuadrado, M. J. (2016) · Rheumatology · doi:10.1093/rheumatology/kev445 · Cited by 35
Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome
Pengo, V. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14896 · Cited by 34
Self-citationAntiphospholipid Antibody Syndrome
Sangle, N. A., & Smock, K. J. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0325-rsr.1 · Cited by 34
Płazak, W., Pasowicz, M., Kostkiewicz, M., Podolec, J., Pająk, L. T., Musiał, J., & Podolec, P. S. (2011) · Inflammation Research · doi:10.1007/s00011-011-0358-x · Cited by 34
Conformation of beta2glycoprotein I and its effect on coagulation
Ninivaggi, M., Kelchtermans, H., Lindhout, T., & de Laat, B. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.08.269 · Cited by 34
Depreter, B., & Devreese, K. M. J. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0978 · Cited by 34
Canti, V., Rosso, S. D., Tonello, M., Lucianò, R., Hoxha, A., Coletto, L. A., Tessitore, I. V., Rosa, S., Manfredi, A. A., Castiglioni, M. T., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.170751 · Cited by 34
Vanoverschelde, L., Kelchtermans, H., Musial, J., de Laat, B., & Devreese, K. M. J. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12207 · Cited by 33
Comparison of six dilute Russell viper venom time lupus anticoagulant screen/confirm assay kits
Fritsma, G., & McGlasson, D. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0033-1334865 · Cited by 33
Hoxha, A., Ruffatti, A., Mattia, E., Meneghel, L., Tonello, M., Salvan, E., Pengo, V., & Punzi, L. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-1129 · Cited by 33
Self-citationNovel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome
Wijetilleka, S., Scoble, T., & Khamashta, M. A. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328354ae8c · Cited by 33
Mondejar, R., Rodríguez, C. G., de Miera, F. J. T., Madrid, E. M., Zohoury, N., Mähler, M., Losquiño, I. R., & Fabiani, F. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.047 · Cited by 33
Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome
Sciascia, S., Bertolaccini, M. L., Roccatello, D., & Khamashta, M. A. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201985 · Cited by 33
Management of acquired haemophilia A
Scharf, R. E., Dobbelstein, C. E., Werwitzke, S., & Tiede, A. (2015) · Hämostaseologie · doi:10.5482/hamo-14-11-0064 · Cited by 33
Yang, Y.-J., Yun, G.-W., Song, I., Baek, S.-W., Lee, K.-S., Ryu, H. W., Lee, M.-W., Lee, H. J., Yun, H., Kim, S., et al. (2011) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2011.26.4.449 · Cited by 33
Metadata
- Authors
- PENGO, V., TRIPODI, A., REBER, G., RAND, J. H., ORTEL, T. L., GALLI, M., & DE GROOT, P. G.
- Affiliations
- University of Padua (IT)
- University of Milan (IT)
- University Hospital of Geneva (CH)
- Montefiore Medical Center (US)
- Duke Medical Center (US)
- Corresponding author
- PENGO, V.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 7
- Issue
- 10
- Pages
- 1737-1740
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W2069797332
- Cited by
- 1,197
- References
- 21
- Citations by year
- 2026: 20 · 2025: 32 · 2024: 53 · 2023: 55 · 2022: 65 · 2021: 89 · 2020: 99 · 2019: 101 · 2018: 88 · 2017: 82 · 2016: 80 · 2015: 75 · 2014: 81 · 2013: 69 · 2012: 82
- FWCI
- 48.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
- Keywords
- lupus anticoagulant, patient selection, activated partial thromboplastin time, cut-off values, interpretation of results, diagnostic guidelines
- MeSH terms
- Anticoagulants, Blood Coagulation, Blood Specimen Collection, Female, Humans, Indicators and Reagents, Male, Partial Thromboplastin Time, Phospholipids, Pregnancy, Pregnancy Complications, Hematologic, Prothrombin Time, Specimen Handling, Vitamin K, Artifacts, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
